Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of FLOT as first-line treatment for advanced gastric cancer with/without severe peritoneal metastasis: Results of dose-finding part.
Authors
Kazuhiro Shiraishi
Department of Medical Oncology, Nagoya Medical Center, Nagoya, Japan
Kazuhiro Shiraishi , Toshiki Masuishi , Takatsugu Ogata , Kyoko Kato , Keiji Sugiyama , Natsuki Nishikawa , Chiho Kudo , Natsumi Takayanagi , Yukiya Narita , Hiroraki Uda , Shigenori Kadowaki , Masashi Ando , Chiyoe Kitagawa , Masato Kataoka , Kei Muro , Kumiko Shibata
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
041200044
DOI
10.1200/JCO.2022.40.4_suppl.298
Abstract #
298
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Impact of first-line fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with advanced gastroesophageal adenocarcinoma: A retrospective analysis.
First Author: Aline Da Rocha Lino
Poster
2017 ASCO Annual Meeting
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.
First Author: Ralf Hofheinz
Poster
2012 ASCO Annual Meeting
Tolerability and efficacy of a biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin regimen (TFOX) in previously advanced metastatic gastric and oesogastric junction (AGC) adenocarcinoma.
First Author: Simon Pernot
Poster
2012 ASCO Annual Meeting
Prognostic role of microRNA polymorphisms in advanced gastric cancer patients.
First Author: Linnea Stenholm